Setting

Europe Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity

Published: 30 Apr 2023 | Report Code: 10248438 | Pages: 186

Europe Clinical Trials Market was valued at valued at $10,939.1 million in 2022 and will grow by 6.4% annually over 2022-2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments. Highlighted with 99 tables and 79 figures, this 186-page report “Europe Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Europe Clinical Trials Market and all its sub-segments through extensively detailed classifications.

 

Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides a forecast from 2023 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

 

In-depth qualitative analyses include the identification and investigation of the following aspects:
•  Market Structure 
•  Growth Drivers 
•  Restraints and Challenges
•  Emerging Product Trends & Market Opportunities
•  Porter’s Five Forces

 

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe Clinical Trials Market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country.

 

Based on Product Category, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Trials of Drugs
    o  Small Molecule Drugs
    o  Vaccines
    o  Cell & Gene Therapy
    o  Other Drugs
•  Trials of Devices
•  Trials of Procedures

 

Based on Phase, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Phase I
•  Phase II
•  Phase III
•  Phase IV

 

By Design, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Interventional Studies
    o  Randomized Control Trial
    o  Adaptive Clinical Trial
    o  Non-randomized Control Trial
•  Observational Studies
    o  Cohort Study
    o  Case Control Study
    o  Cross Sectional Study
    o  Ecological Study
•  Expanded Access Trials

 

By Service Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Protocol Designing
•  Site Identification
•  Patient Recruitment
•  Laboratory Services
•  Bioanalytical Testing Services
•  Clinical Trial Data Management Services
•  Clinical Trial Supply & Logistic Services
•  Decentralized Clinical Trial Services
•  Medical Device Testing Services
•  Other Clinical Trial Services

 

By Indication, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Oncology
•  Infectious Diseases
•  Cardiology
•  Obesity
•  Diabetes
•  Neurology
•  Immunology
•  Pain Management
•  Other Indications

 

By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Pharmaceutical and Biotechnological Companies
•  Clinical Research Organizations
•  Clinical Testing Laboratories
•  Other End Users

 

Geographically, the following national/local markets are fully investigated:
•  Germany
•  UK
•  France
•  Spain
•  Italy
•  Russia 
•  Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) 

 

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031. The breakdown of each national market by Phase, Design, and Indication over the forecast years are also included. The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

 

Selected Key Players: 


Accell Clinical Research LLC
Charles River Laboratories
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America (Covance Inc.)
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PhlexEurope
PRA Health Sciences
Sanofi SA
SGS SA (SGS Life Sciences)
Syneos Health Inc.
Wuxi AppTec Inc. 


(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table of Contents:

1 Introduction    10
1.1 Industry Definition and Research Scope    10
1.1.1 Industry Definition    10
1.1.2 Research Scope    11
1.2 Research Methodology    14
1.2.1 Overview of Market Research Methodology    14
1.2.2 Market Assumption    15
1.2.3 Secondary Data    15
1.2.4 Primary Data    15
1.2.5 Data Filtration and Model Design    16
1.2.6 Market Size/Share Estimation    17
1.2.7 Research Limitations    18
1.3 Executive Summary    19
2 Market Overview and Dynamics    22
2.1 Market Size and Forecast    22
2.1.1 Impact of COVID-19 on World Economy    24
2.1.2 Impact of COVID-19 on the Market    27
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery    29
2.2 Major Growth Drivers    33
2.3 Market Restraints and Challenges    40
2.4 Emerging Opportunities and Market Trends    43
2.5 Porter’s Fiver Forces Analysis    47
3 Segmentation of Europe Market by Product Category    51
3.1 Market Overview by Product Category    51
3.2 Trials of Drugs    53
3.2.1 Small Molecule Drugs    54
3.2.2 Vaccines    55
3.2.3 Cell & Gene Therapy    56
3.2.4 Other Drugs    57
3.3 Trials of Devices    58
3.4 Trials of Procedures    59
4 Segmentation of Europe Market by Phase    60
4.1 Market Overview by Phase    60
4.2 Phase I    62
4.3 Phase II    63
4.4 Phase III    64
4.5 Phase IV    65
5 Segmentation of Europe Market by Design    66
5.1 Market Overview by Design    66
5.2 Interventional Studies    68
5.2.1 Randomized Control Trial    70
5.2.2 Adaptive Clinical Trial    71
5.2.3 Non-randomized Control Trial    72
5.3 Observational Studies    73
5.3.1 Cohort Study    75
5.3.2 Case Control Study    76
5.3.3 Cross Sectional Study    77
5.3.4 Ecological Study    78
5.4 Expanded Access Trials    79
6 Segmentation of Europe Market by Service Type    80
6.1 Market Overview by Service Type    80
6.2 Protocol Designing    82
6.3 Site Identification    83
6.4 Patient Recruitment    84
6.5 Laboratory Services    85
6.6 Bioanalytical Testing Services    86
6.7 Clinical Trial Data Management Services    87
6.8 Clinical Trial Supply & Logistic Services    88
6.9 Decentralized Clinical Trial Services    89
6.10 Medical Device Testing Services    90
6.11 Other Clinical Trial Services    91
7 Segmentation of Europe Market by Indication    92
7.1 Market Overview by Indication    92
7.2 Oncology    94
7.3 Infectious Diseases    95
7.4 Cardiology    96
7.5 Obesity    97
7.6 Diabetes    98
7.7 Neurology    99
7.8 Immunology    100
7.9 Pain Management    101
7.10 Other Indications    102
8 Segmentation of Europe Market by End User    103
8.1 Market Overview by End User    103
8.2 Pharmaceutical and Biotechnological Companies    105
8.3 Clinical Research Organizations    106
8.4 Clinical Testing Laboratories    107
8.5 Other End Users    108
9 European Market 2021-2031 by Country    109
9.1 Overview of European Market    109
9.2 Germany    112
9.3 U.K.    114
9.4 France    116
9.5 Spain    118
9.6 Italy    120
9.7 Russia    122
9.8 Rest of European Market    124
10 Competitive Landscape    126
10.1 Overview of Key Vendors    126
10.2 New Product Launch, Partnership, Investment, and M&A    130
10.3 Company Profiles    131
Accell Clinical Research LLC    131
Charles River Laboratories    133
ClinDatrix Inc    136
Clinipace    137
Eli Lilly and Company    139
F. Hoffmann-La Roche Ltd.    142
ICON PLC    145
IQVIA Holdings, Inc.    148
Laboratory Corporation of America (Covance Inc.)    152
Novo Nordisk AS    156
PAREXEL International Corporation    159
Pfizer Inc.    163
Pharmaceutical Product Development LLC    168
Phlexglobal    171
PRA Health Sciences    173
Sanofi SA    175
SGS SA (SGS Life Sciences)    178
Syneos Health Inc.    181
Wuxi AppTec Inc.    184
RELATED REPORTS    186

 

List of Tables:

Table 1. Snapshot of Europe Clinical Trials Market in Balanced Perspective, 2022-2031    20
Table 2. Total Number of Registered Clinical Studies Worldwide, 2010-2021    23
Table 3. World Economic Outlook, 2021-2031    25
Table 4. World Economic Outlook, 2021-2023    26
Table 5. Scenarios for Economic Impact of Ukraine Crisis    30
Table 6. World Health Spending by Region, $ bn, 2013-2020    39
Table 7. Main Product Trends and Market Opportunities in Europe Clinical Trials Market    43
Table 8. Europe Clinical Trials Market by Product Category, 2021-2031, $ mn    51
Table 9. Europe Clinical Trials Market: Trials of Drugs by Drug Type, 2021-2031, $ mn    53
Table 10. Europe Clinical Trials Market by Phase, 2021-2031, $ mn    60
Table 11. Europe Clinical Trials Market by Design, 2021-2031, $ mn    66
Table 12. Europe Clinical Trials Market: Interventional Studies by Segment, 2021-2031, $ mn    69
Table 13. Europe Clinical Trials Market: Observational Studies by Segment, 2021-2031, $ mn    74
Table 14. Europe Clinical Trials Market by Service Type, 2021-2031, $ mn    80
Table 15. Europe Clinical Trials Market by Indication, 2021-2031, $ mn    92
Table 16. Europe Clinical Trials Market by End User, 2021-2031, $ mn    103
Table 17. Europe Clinical Trials Market by Country, 2021-2031, $ mn    111
Table 18. Germany Clinical Trials Market by Phase, 2021-2031, $ mn    113
Table 19. Germany Clinical Trials Market by Design, 2021-2031, $ mn    113
Table 20. Germany Clinical Trials Market by Indication, 2021-2031, $ mn    113
Table 21. U.K. Clinical Trials Market by Phase, 2021-2031, $ mn    115
Table 22. U.K. Clinical Trials Market by Design, 2021-2031, $ mn    115
Table 23. U.K. Clinical Trials Market by Indication, 2021-2031, $ mn    115
Table 24. France Clinical Trials Market by Phase, 2021-2031, $ mn    117
Table 25. France Clinical Trials Market by Design, 2021-2031, $ mn    117
Table 26. France Clinical Trials Market by Indication, 2021-2031, $ mn    117
Table 27. Spain Clinical Trials Market by Phase, 2021-2031, $ mn    119
Table 28. Spain Clinical Trials Market by Design, 2021-2031, $ mn    119
Table 29. Spain Clinical Trials Market by Indication, 2021-2031, $ mn    119
Table 30. Italy Clinical Trials Market by Phase, 2021-2031, $ mn    121
Table 31. Italy Clinical Trials Market by Design, 2021-2031, $ mn    121
Table 32. Italy Clinical Trials Market by Indication, 2021-2031, $ mn    121
Table 33. Russia Clinical Trials Market by Phase, 2021-2031, $ mn    123
Table 34. Russia Clinical Trials Market by Design, 2021-2031, $ mn    123
Table 35. Russia Clinical Trials Market by Indication, 2021-2031, $ mn    123
Table 36. Clinical Trials Market in Rest of Europe by Country, 2021-2031, $ mn    125
Table 37. Percentage of Registered Studies by Location (as of February 24, 2022)    128
Table 38. Percentage of Recruiting Studies by Location (as of February 24, 2022)    128
Table 39. Accell Clinical Research LLC: Company Snapshot    131
Table 40. Accell Clinical Research LLC: Business Segmentation    132
Table 41. Accell Clinical Research LLC: Product Portfolio    132
Table 42. Charles River Laboratories: Company Snapshot    133
Table 43. Charles River Laboratories: Product Portfolio    134
Table 44. Charles River Laboratories: Breakdown of Revenue by Division    134
Table 45. Charles River Laboratories: Breakdown of Revenue by Region    135
Table 46. ClinDatrix Inc: Company Snapshot    136
Table 47. Clinipace: Company Snapshot    137
Table 48. Clinipace: Product Portfolio    138
Table 49. Eli Lilly and Company: Company Snapshot    139
Table 50. Eli Lilly and Company: Pharmaceutical Brands    140
Table 51. Eli Lilly and Company: Clinical Trial Service    140
Table 52. Eli Lilly and Company: Breakdown of Revenue by Therapeutic Area    140
Table 53. Eli Lilly and Company: Breakdown of Revenue by Region    141
Table 54. F. Hoffmann-La Roche: Company Snapshot    142
Table 55. F. Hoffmann-La Roche: Clinical Trial Service    142
Table 56. F. Hoffmann-La Roche: Business Segmentation    143
Table 57. F. Hoffmann-La Roche: Revenue by Region    143
Table 58. ICON Plc: Company Snapshot    145
Table 59. ICON Plc: Business Segmentation    145
Table 60. ICON Plc: Product Portfolio    146
Table 61. ICON Plc: Revenue by Region, 2020, 6
Table 62. IQVIA Holdings Inc.: Company Snapshot    148
Table 63. IQVIA Holdings Inc.: Business Segmentation    149
Table 64. IQVIA Holdings Inc.: Revenue by Region, 2020, 9
Table 65. IQVIA Holdings Inc.: Product Portfolio    150
Table 66. Covance Inc.: Company Snapshot    152
Table 67. Covance Inc.: Product Portfolio    153
Table 68. Covance Inc.: Revenue by Region, 2020, 4
Table 69. Novo Nordisk: Company Snapshot    156
Table 70. Novo Nordisk: Product Portfolio    157
Table 71. Novo Nordisk: Breakdown of Revenue by Business Segment    158
Table 72. Novo Nordisk: Breakdown of Revenue by Region    158
Table 73. PAREXEL International Corporation: Company Snapshot    159
Table 74. PAREXEL International Corporation: Business Segmentation    160
Table 75. PAREXEL International Corporation: Revenue by Region, 2018, 0
Table 76. PAREXEL International Corporation: Product Portfolio    161
Table 77. Pfizer Inc.: Company Snapshot    163
Table 78. Pfizer Inc.: Business Segmentation    164
Table 79. Pfizer Inc.: Breakdown of Revenue by Product Category    164
Table 80. Pfizer Inc.: Breakdown of Revenue by Region    165
Table 81. Pfizer Inc.: Product Portfolio    165
Table 82. Pfizer Inc.: Revenue, 2018-2020, $ bn    166
Table 83. Pharmaceutical Product Development LLC (PPD): Company Snapshot    168
Table 84. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Division    169
Table 85. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Region    169
Table 86. Phlexglobal: Company Snapshot    171
Table 87. PRA Health Sciences Inc.: Company Snapshot    173
Table 88. PRA Health Sciences Inc.: Business Segmentation    174
Table 89. PRA Health Sciences Inc.: Revenue by Region, 2018, 4
Table 90. Sanofi: Company Snapshot    175
Table 91. Sanofi: Business Segmentation    176
Table 92. Sanofi: Breakdown of Revenue by Region    176
Table 93. SGS SA (SGS Life Sciences): Company Snapshot    178
Table 94. SGS SA (SGS Life Sciences): Business Segmentation    179
Table 95. SGS SA (SGS Life Sciences): Revenue by Region, 2018, 9
Table 96. Syneos Health Inc.: Company Snapshot    181
Table 97. Syneos Health Inc.: Business Segmentation    182
Table 98. Syneos Health Inc.: Revenue by Region, 2020, 2
Table 99. WuXi AppTec Inc.: Company Snapshot    184

 

List of Figures:

Figure 1. Research Method Flow Chart    14
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation    17
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2031    19
Figure 4. Europe Clinical Trials Market, 2021-2031, $ mn    22
Figure 5. Impact of COVID-19 on Business    27
Figure 6. Primary Drivers and Impact Factors of Europe Clinical Trials Market    33
Figure 7. Percentage of Trial Participants by Country, 2015-2019    36
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million    37
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million    38
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060    38
Figure 11. Primary Restraints and Impact Factors of Europe Clinical Trials Market    40
Figure 12. Investment Opportunity Analysis    44
Figure 13. Porter’s Fiver Forces Analysis of Europe Clinical Trials Market    47
Figure 14. Breakdown of Europe Clinical Trials Market by Product Category, 2021-2031, % of Revenue    52
Figure 15. Europe Addressable Market Cap in 2023-2031 by Product Category, Value ($ mn) and Share (%)    52
Figure 16. Europe Clinical Trials Market by Product Category: Trials of Drugs, 2021-2031, $ mn    53
Figure 17. Europe Clinical Trials Market by Trials of Drugs: Small Molecule Drugs, 2021-2031, $ mn    54
Figure 18. Europe Clinical Trials Market by Trials of Drugs: Vaccines, 2021-2031, $ mn    55
Figure 19. Europe Clinical Trials Market by Trials of Drugs: Cell & Gene Therapy, 2021-2031, $ mn    56
Figure 20. Europe Clinical Trials Market by Trials of Drugs: Other Drugs, 2021-2031, $ mn    57
Figure 21. Europe Clinical Trials Market by Product Category: Trials of Devices, 2021-2031, $ mn    58
Figure 22. Europe Clinical Trials Market by Product Category: Trials of Procedures, 2021-2031, $ mn    59
Figure 23. Breakdown of Europe Clinical Trials Market by Phase, 2021-2031, % of Sales Revenue    61
Figure 24. Europe Addressable Market Cap in 2023-2031 by Phase, Value ($ mn) and Share (%)    61
Figure 25. Europe Clinical Trials Market by Phase: Phase I, 2021-2031, $ mn    62
Figure 26. Europe Clinical Trials Market by Phase: Phase II, 2021-2031, $ mn    63
Figure 27. Europe Clinical Trials Market by Phase: Phase III, 2021-2031, $ mn    64
Figure 28. Europe Clinical Trials Market by Phase: Phase IV, 2021-2031, $ mn    65
Figure 29. Breakdown of Europe Clinical Trials Market by Design, 2021-2031, % of Sales Revenue    67
Figure 30. Europe Addressable Market Cap in 2023-2031 by Design, Value ($ mn) and Share (%)    67
Figure 31. Europe Clinical Trials Market by Design: Interventional Studies, 2021-2031, $ mn    68
Figure 32. Europe Clinical Trials Market by Interventional Studies: Randomized Control Trial, 2021-2031, $ mn    70
Figure 33. Europe Clinical Trials Market by Interventional Studies: Adaptive Clinical Trial, 2021-2031, $ mn    71
Figure 34. Europe Clinical Trials Market by Interventional Studies: Non-randomized Control Trial, 2021-2031, $ mn    72
Figure 35. Europe Clinical Trials Market by Design: Observational Studies, 2021-2031, $ mn    73
Figure 36. Europe Clinical Trials Market by Observational Studies: Cohort Study, 2021-2031, $ mn    75
Figure 37. Europe Clinical Trials Market by Observational Studies: Case Control Study, 2021-2031, $ mn    76
Figure 38. Europe Clinical Trials Market by Observational Studies: Cross Sectional Study, 2021-2031, $ mn    77
Figure 39. Europe Clinical Trials Market by Observational Studies: Ecological Study, 2021-2031, $ mn    78
Figure 40. Europe Clinical Trials Market by Design: Expanded Access Trials, 2021-2031, $ mn    79
Figure 41. Breakdown of Europe Clinical Trials Market by Service Type, 2021-2031, % of Revenue    81
Figure 42. Europe Addressable Market Cap in 2023-2031 by Service Type, Value ($ mn) and Share (%)    81
Figure 43. Europe Clinical Trials Market by Service Type: Protocol Designing, 2021-2031, $ mn    82
Figure 44. Europe Clinical Trials Market by Service Type: Site Identification, 2021-2031, $ mn    83
Figure 45. Europe Clinical Trials Market by Service Type: Patient Recruitment, 2021-2031, $ mn    84
Figure 46. Europe Clinical Trials Market by Service Type: Laboratory Services, 2021-2031, $ mn    85
Figure 47. Europe Clinical Trials Market by Service Type: Bioanalytical Testing Services, 2021-2031, $ mn    86
Figure 48. Europe Clinical Trials Market by Service Type: Clinical Trial Data Management Services, 2021-2031, $ mn    87
Figure 49. Europe Clinical Trials Market by Service Type: Clinical Trial Supply & Logistic Services, 2021-2031, $ mn    88
Figure 50. Europe Clinical Trials Market by Service Type: Decentralized Clinical Trial Services, 2021-2031, $ mn    89
Figure 51. Europe Clinical Trials Market by Service Type: Medical Device Testing Services, 2021-2031, $ mn    90
Figure 52. Europe Clinical Trials Market by Service Type: Other Clinical Trial Services, 2021-2031, $ mn    91
Figure 53. Breakdown of Europe Clinical Trials Market by Indication, 2021-2031, % of Revenue    93
Figure 54. Europe Addressable Market Cap in 2023-2031 by Indication, Value ($ mn) and Share (%)    93
Figure 55. Europe Clinical Trials Market by Indication: Oncology, 2021-2031, $ mn    94
Figure 56. Europe Clinical Trials Market by Indication: Infectious Diseases, 2021-2031, $ mn    95
Figure 57. Europe Clinical Trials Market by Indication: Cardiology, 2021-2031, $ mn    96
Figure 58. Europe Clinical Trials Market by Indication: Obesity, 2021-2031, $ mn    97
Figure 59. Europe Clinical Trials Market by Indication: Diabetes, 2021-2031, $ mn    98
Figure 60. Europe Clinical Trials Market by Indication: Neurology, 2021-2031, $ mn    99
Figure 61. Europe Clinical Trials Market by Indication: Immunology, 2021-2031, $ mn    100
Figure 62. Europe Clinical Trials Market by Indication: Pain Management, 2021-2031, $ mn    101
Figure 63. Europe Clinical Trials Market by Indication: Other Indications, 2021-2031, $ mn    102
Figure 64. Breakdown of Europe Clinical Trials Market by End User, 2021-2031, % of Revenue    103
Figure 65. Europe Addressable Market Cap in 2023-2031 by End User, Value ($ mn) and Share (%)    104
Figure 66. Europe Clinical Trials Market by End User: Pharmaceutical and Biotechnological Companies, 2021-2031, $ mn    105
Figure 67. Europe Clinical Trials Market by End User: Clinical Research Organizations, 2021-2031, $ mn    106
Figure 68. Europe Clinical Trials Market by End User: Clinical Testing Laboratories, 2021-2031, $ mn    107
Figure 69. Europe Clinical Trials Market by End User: Other End Users, 2021-2031, $ mn    108
Figure 70. Breakdown of European Clinical Trials Market by Country, 2022 and 2031, % of Revenue    110
Figure 71. Contribution to Europe 2023-2031 Cumulative Market by Country, Value ($ mn) and Share (%)    111
Figure 72. Clinical Trials Market in Germany, 2021-2031, $ mn    112
Figure 73. Clinical Trials Market in U.K., 2021-2031, $ mn    114
Figure 74. Clinical Trials Market in France, 2021-2031, $ mn    116
Figure 75. Clinical Trials Market in Spain, 2021-2031, $ mn    118
Figure 76. Clinical Trials Market in Italy, 2021-2031, $ mn    120
Figure 77. Clinical Trials Market in Russia, 2021-2031, $ mn    122
Figure 78. Clinical Trials Market in Rest of Europe, 2021-2031, $ mn    124
Figure 79. Growth Stage of Europe Clinical Trials Industry over the Forecast Period    126
Selected Key Players:

Accell Clinical Research LLC
Charles River Laboratory
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PRA Health Sciences
Sanofi SA
SGS SA
Syneos Health Inc.
Wuxi AppTec Inc. 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)